Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma (AADI)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2013 by Aurolab.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Aurolab Identifier:
First received: July 20, 2011
Last updated: January 2, 2013
Last verified: January 2013
The purpose of this study is to evaluate the efficacy and safety of Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction in patients with refractory glaucoma.

Condition Intervention Phase
Device: Artificial drainage implant
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma

Resource links provided by NLM:

Further study details as provided by Aurolab:

Primary Outcome Measures:
  • Intra Ocular Pressure (IOP) [ Time Frame: One year ]
    Mean Intraocular pressure (IOP) reduction from pre operative IOP

Secondary Outcome Measures:
  • Success rate [ Time Frame: one year ]
    Success rate (defined as Inraocular pressure (IOP) of 5mmHg to 20 mmHg and at least a 20% reduction in IOP without visually devastating complications or additional glaucoma surgery)

  • Number of patients with adverse events as a measure of safety [ Time Frame: one year ]
    to assess the incidence of post operative adverse events

Estimated Enrollment: 30
Study Start Date: July 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Artificial drainage implant
Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
Device: Artificial drainage implant
Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
Other Name: AADI

Detailed Description:
Aurolab Artificial Drainage Implant is a non resistant tube device based on Baerveldt implant. It reduces intra ocular pressure by draining aqueous from anterior chamber into sub-conjunctival space formed around base of the implant. Reduction of intraocular pressure prevents further damage to optic nerve and functional visual field loss in advanced refractory glaucoma.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Significant optic nerve damage and visual field loss due to glaucoma in eligible eyes
  • Eligible eyes is considered at high risk of failure/complication following conventional filtering surgery
  • Eyes with uncontrolled glaucoma with prior history of Filtering surgery/Uveitic/ Neovascular/Developmental glaucomas
  • IOP≥18 mm of Hg with or without anti glaucoma medications
  • If taking glaucoma medications, stable dose for 6 weeks

Exclusion Criteria:

  • Age<18 years
  • Eyes with uncontrolled glaucoma expected to have favorable post-operative outcome by conventional trabeculectomy
  • Corneal abnormalities that would preclude accurate IOP readings
  • Uncontrolled systemic diseases
  • Endothelial cell count<1800cells/mm
  • Any other active ocular disease,(active uveitis, ocular infection)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01401088

Contact: Dr. Prashanth Ranganath, MBBS., MS., +91 452 4356100 ext 118
Contact: Mr.S.Karthi Kumar, M.Pahrmacy +91 452 4356100 ext 229

Aravind Eye Hospital Recruiting
Madurai, Tamilnadu, India, 625020
Contact: Mr. S.Karthi Kumar, M. Pharmacy    +91 452 3096100 ext 229   
Contact: Ms. Sophia , M.Sc    +91 452 4356100 ext 364   
Principal Investigator: Dr. Prashanth Ranganath, MBBS., MS.,         
Sponsors and Collaborators
Principal Investigator: Dr. Prashanth Ranganath, MBBS., MS., Aravind Eye Hospital, Madurai
  More Information

Responsible Party: Aurolab Identifier: NCT01401088     History of Changes
Other Study ID Numbers: 1PN1011049
Study First Received: July 20, 2011
Last Updated: January 2, 2013

Keywords provided by Aurolab:
patient with refractory glaucoma

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases processed this record on May 22, 2017